NCT02219178View on ClinicalTrials.gov

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2019

Study Completion Date

April 30, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

lenalidomide

25mg days 1 - 14 of 21 day schedule

DRUG

Subcutaneous bortezomib

1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule

DRUG

Dexamethasone

20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule

Trial Locations (8)

Unknown

University Hospital Waterford, Waterford

Cork University Hospital, Cork

Beaumont Hospital, Dublin

Mater Misericordiae University Hospital, Dublin

St James's Hospital, Dublin

University Hospital Galway, Galway

University Hospital Limerick, Limerick

Midlands Regional Hospital, Tullamore

All Listed Sponsors
lead

Cancer Trials Ireland

NETWORK

NCT02219178 - Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | Biotech Hunter | Biotech Hunter